1
In general, strontium ranelate therapy did not seem to be associated with an increased risk of adverse events.
2
Treatment with strontium ranelate was calculated against a no-treatment option to evaluate whether it could be given cost-effectively.
3
An incremental analysis against alendronate was also conducted to estimate the cost-effectiveness of strontium ranelate relative to a current standard treatment.
4
From the algorithm used, it is seen that strontium ranelate can be used cost-effectively in women at relatively high risk of osteoporotic fracture.
5
Some nervous system disorders, including mental impairment, disturbed consciousness, memory loss and seizures, were also more common in patients randomised to strontium ranelate.
6
If it were believed that the efficacy of strontium ranelate is dependent on either age or absolute risk, this would need to be proven.
7
Conclusions: Strontium ranelate was shown to be clinically effective in the prevention of osteoporotic fractures.
8
Strontium ranelate provided gains in QALYs compared with no treatment in women with sufficient calcium and vitamin D intakes.